When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?
McCall
Anthony L
AL
University of Virginia Health System, Diabetes and Hormone Center of Excellence, Charlottesville, VA 22908, USA. alm3j@virginia.edu